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Abstract
Background Comorbidities negatively affect prognosis
more strongly in heart failure with preserved (HFpEF) than
with reduced (HFrEF) ejection fraction. Their comparative
impact on physical impairment in HFpEF and HFrEF has
not been evaluated so far.
Methods and results The frequency of 12 comorbidities
and their impact on NYHA class and SF-36 physical func-
tioningscore(SF-36PF)wereevaluatedin1,294patientswith
HFpEF and 2,785 with HFrEF. HFpEF patients had lower
NYHA class(2.0 ± 0.6vs.2.4 ± 0.6,p\0.001)andhigher
SF-36PFscore(54.4 ± 28.3vs.54.4 ± 27.7,p\0.001).All
comorbidities were signiﬁcantly (p\0.05) more frequent in
HFrEF, except hypertension and obesity, which were more
frequentinHFpEF(p\0.001).Adjustingforageandgender,
COPD, anemia, hyperuricemia, atrial ﬁbrillation, renal dys-
function, cerebrovascular disease and diabetes had a similar
(p for interaction [0.05) negative effect in both groups.
Obesity, coronary artery disease and peripheral arterial
occlusive disease exerted a signiﬁcantly (p\0.05) more
adverse effect in HFpEF, while hypertension and hyperlip-
idemia were associated with fewer (p\0.05) symptoms in
HFrEF only. The total impact of comorbidities on NYHA
(AUC for prediction of NYHA III/IV vs. I/II) and SF-36 PF
(r
2) in multivariate analyses was approximately 1.5-fold
higherinHFpEF,andalsomuchstrongerthantheimpactofa
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Conclusion The impact of comorbidities on physical
impairment is higher in HFpEF than in HFrEF. This should
be considered in the differential diagnosis and in the
treatment of patients with HFpEF.
Keywords Heart failure with preserved ejection fraction 
Heart failure with reduced ejection fraction 
Comorbidities  Physical impairment
Introduction
Congestive heart failure (CHF) is a prevalent disease and
a heavy burden for health-care systems [1] as well as for
the affected individual. The leading symptom is an
impairment of exercise performance, limiting patients’
functioning and quality of daily life. However, physical
limitations in individuals with CHF are only partly
explained by cardiac function [2]. Comorbidities are
prevalent in CHF [3] and, with the aging of Western
populations, will be even more so in the future. They are
known to strongly inﬂuence the overall prognosis and
health-care utilization [4]. However, data are limited
regarding the inﬂuence of comorbidities on signs and
symptoms in CHF. Furthermore, most analyses dealing
with the impact of comorbidities evaluated the inﬂuence
of one single disease entity at a time. Dyspnea and a
limitation in exercise capacity are usually the complaints
in CHF [5] that induce a specialist consultation to con-
ﬁrm a suspicion of CHF. They are the most important
subjective parameters to evaluate the course of the dis-
ease in an individual. More than 50% of patients with
the clinical syndrome of heart failure have a normal left
ventricular ejection fraction [6, 7]. These cases can
therefore be termed ‘‘heart failure with preserved ejec-
tion fraction’’ (or HFpEF) as compared to ‘‘heart failure
with reduced ejection fraction’’ (or HFrEF). Although the
overall prognosis in HFpEF is similarly grim as in
HFrEF [6, 7], patients frequently die from non-cardiac
causes and less often from heart failure than HFrEF
patients [8–10]. Comorbidities are therefore believed to
play a more important role in HFpEF than in HFrEF
[11]. Still, knowledge about the impact of such comor-
bidities on symptoms in HFpEF is even more limited
than in HFrEF.
We therefore aimed to compare the frequency of 12
major comorbidities and their impact on NYHA class and
SF-36 physical functioning (PF) score in a large nation-
wide sample of CHF patients. We hypothesized that the
impact of comorbidities would be higher in patients with
HFpEF than with HFrEF.
Methods
Study design and setting
We performed a retrospective cross-sectional analysis of
all patients who were screened for clinical trials performed
within the framework of the German Competence Network
Heart Failure (CNHF).
The CNHF is a government-sponsored nation-wide
network consisting of infrastructure and scientiﬁc projects
dedicated to improvement in efﬁciency and efﬁcacy of
research in CHF, quality of care for CHF patients, and
educating the public about CHF (for details see Mehrhof
et al. [12.] and (www.ghfn.eu)). All trials within the CNHF
comply with the declaration of Helsinki; the protocols were
approved by the responsible ethics committees and all
patients gave written informed consent. Diagnostic proce-
dures within CNHF were performed according to standard
operating procedures (SOP). For all clinical projects within
the framework of CNHF, a harmonized basic clinical data
set consisting of 190 items has been developed including
echocardiographic parameters. Echocardiography was
performed according to international guidelines transferred
into CNHF SOPs. Data storage and analysis were per-
formed at a central data management unit.
Within the basic data set, information was available on
the following 12 major comorbidities that are typical for an
elderly heart failure population [4]: presence of coronary
artery disease (CAD), peripheral arterial occlusive disease
(PAOD) and cerebrovascular disease (i.e., history of stroke
or transitory ischemic attack). These were classiﬁed
according to medical history. Chronic obstructive pul-
monary disease (COPD), diabetes mellitus, hypertension,
hyperlipidemia and hyperuricemia were classiﬁed accord-
ing to medical history or respective medication. Renal
dysfunction (i.e., eGFR\60 ml/min per m
2; eGFR calcu-
lated by MDRD formula [13]) and anemia (i.e., Hb\12 or
13 g/dl for women or men, respectively) were classiﬁed
according to history and pathological laboratory values at
screening. Obesity was deﬁned as a body mass index
[30 kg/m
2; diagnosis of atrial ﬁbrillation was based on
baseline ECGs and therefore represents persistent or per-
manent atrial ﬁbrillation only. NYHA functional class was
assessed by screening physicians and quality of life by the
SF-36 standard questionnaire [14].
Patients
Data were assessed at the individual patient level at the
screening visit for each trial and were pooled for this
analysis across ﬁve interventional and six non-interven-
tional trials (for details see Mehrhof et al. [12]). Patients
were classiﬁed as having CHF by experienced cardiologists
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123at screening, and as having HFpEF when LV-EF was
C50% or HFrEF when LV-EF was \50% on baseline
echocardiography.
Statistical analyses
Baseline data were presented as mean (standard deviation)
for quantitative variables, and absolute number (%) for
frequencies. The t test and Fisher’s test were used for
comparisons between groups for quantitative variables and
frequencies, respectively.
The impact of different comorbidities on NYHA class
was assessed by ordinal regression, adjusted for age, sex
and CHF group (HFrEF or HFpEF). In preliminary anal-
yses, the interaction term of the CHF group and comor-
bidity was included to examine whether the effects of the
comorbidity on NYHA class in HFrEF and HFpEF patients
should be considered to be of the same or different size. If
the p value for interaction was C0.1, a common estimate of
the odds ratio was presented. In case of a signiﬁcant
(p\0.05) or borderline (0.05 B p\0.1) interaction term,
homogeneity of the odds ratios was not assumed, and
separate estimates in the HFrEF and HFpEF groups were
computed.
The association between comorbidities on the SF-36 PF
scale was analyzed in the same manner, using linear
regression.
Multiple regression analyses (ordinal or linear, respec-
tively) for NYHA class and SF-36 PF were performed,
including all comorbidities as covariates for both groups.
We also included into these analyses two echocardiographic
measures: left ventricular ejection fraction (LV-EF)
describing the severity of systolic dysfunction in HFrEF and
left ventricular end-diastolic diameter (LVD[ED]) reﬂect-
ing impaired ventricular ﬁlling in HFpEF. This allows
weighing the impacts of ventricular dysfunction and
comorbidities on symptoms and physical functioning
against each other.
Based on the multiple regression models, areas under
ROC curves for the prediction of NYHA classes III–IV and
explained variances (R
2) for the prediction of the SF-36
physical functioning scale were computed to illustrate the
explanatory impact of comorbidities on top of sociode-
mography and echocardiographic parameters.
Results
Among 8,368 individuals screened for participation, 4,259
were identiﬁed with CHF. Of these, information was
missing on LV-EF in 150, NYHA class in 25, both LV-EF
and NYHA in 4, and age in 1 patient. Of 4,079 patients
available for analysis, 2,785 (68%) had HFrEF and 1,294
(32%) had HFpEF. Out of these, 3,476 (85.2%) completed
the SF-36 questionnaire. In multivariate logistic regression
analysis including age, sex and CHF group as covariates,
only age signiﬁcantly predicted the completion of the
SF-36 questionnaire.
HFpEF patients were older, more frequently female, had
higher blood pressures and were less intensively treated
with heart failure medications (Table 1). They were also
less symptomatic with a lower mean NYHA class and a
lower number of CHF symptoms per patient with lower
rates for all individual symptoms except peripheral edema
(Table 1 and Fig. 1). SF-36 PF score was higher in HFpEF.
Only hypertension and obesity were more frequent in
HFpEF, while all other comorbidities were observed more
frequently in HFrEF patients. Seven comorbidities did not
show an interaction with CHF group in ordinal regression
analysis, i.e., their inﬂuence on NYHA class and SF-36
PFS was similar in both groups (Table 2). All these
comorbidities had a highly signiﬁcant impact on patients’
symptoms by increasing NYHA class and reducing SF-36
PF score, with COPD and anemia showing the strongest
associations. The remaining ﬁve comorbidities behaved
differently in HFpEF and HFrEF: In HFrEF, hypertension
and hyperlipidemia were associated with a better NYHA
class, while the latter impacted on the NYHA class nega-
tively in HFpEF and was also associated with a worse
SF-36 PF in these patients. CAD had a negative effect on
NYHA class in HFpEF only and its association with lower
SF-36 PF was signiﬁcantly stronger than that observed in
HFrEF patients. Similarly, a negative impact of PAOD on
NYHA class and SF-36 PF was signiﬁcantly stronger in
HFpEF compared with HFrEF. Obesity signiﬁcantly
increased NYHA class in HFpEF only, while there was no
signiﬁcant difference in its (negative) impact on SF-36 PF
in both CHF groups.
In multivariate analyses, hyperuricemia, renal dysfunc-
tion, anemia, COPD, cerebrovascular disease and atrial
ﬁbrillation retained their signiﬁcantly negative impact on
NYHA class in HFrEF, while hypertension and hyperlip-
idemia retained their protective effect (Fig. 2a). The
strength of association for the negatively inﬂuencing
comorbidities was similar to that of a reduction in LV-EF
of 10% (which corresponds to a quartile of the distribution
for this parameter in our cohort), with widely overlapping
conﬁdence intervals. In HFpEF, only CAD, anemia,
obesity, COPD and atrial ﬁbrillation had a signiﬁcantly
negative effect in multivariate ordinal regression analysis,
although wider conﬁdence intervals illustrated the lower
statistical power to show inﬂuencing factors due to the
lower subject number in this group. The effect of these
comorbidities appeared to be much stronger than that of an
LVD (ED) lowered by 5 mm (again corresponding to a
quartile in our cohort), the most strongly associated
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123parameter on routine echocardiography in this patient
group. SF-36 PF score was negatively affected in HFrEF
by all comorbidities except for diabetes, hypertension and
hyperlipidemia, with the last two again showing a protec-
tive effect with regard to this parameter (Fig. 2b). The
effects tended to be stronger than that of an LV-EF
reduction. In HFpEF, hyperuricemia, CAD, renal dys-
function, anemia, obesity, COPD, PAOD and atrial ﬁbril-
lation were associated with lower SF-36 PF score. Again,
the effect of reduced LVD (ED) was signiﬁcant but weak in
comparison with comorbidities. LV-EF had no signiﬁcant
effect on HFpEF and the same held true for LVD (ED) in
HFrEF.
Accordingly, adding both echocardiographic variables
as covariates improved the prediction of NYHA classes III
or IV in HFrEF, derived from the multivariate regression
model, while AUC remained virtually unchanged in
HFpEF (Fig. 3a). Expansion of the set of covariates for all
comorbidities further improved the AUC in HFrEF to an
extent similar to that provided by the addition of the
echocardiographic variables. However, in HFpEF, the
increase in AUC was much larger (?0.100 vs. ?0.029),
resulting in a similar AUC as in HFrEF for the ﬁnal
multivariate model that included all covariates, with a
relatively larger share supplied by comorbidities in
HFpEF.
Table 1 Clinical characteristics
* Different by deﬁnition of
groups
HFrEF (n = 2,785) HFpEF (n = 1,294) p value
Age (years) 63 ± 14 67 ± 13 \0.001
Female sex 709 (25.5%) 696 (53.8%) \0.001
Systolic blood pressure (mmHg) 123 ± 20 142 ± 24 \0.001
Diastolic blood pressure (mmHg) 73 ± 12 81 ± 13 \0.001
Heart rate (1/min) 76 ± 17 70 ± 14 \0.001
Medication (n)
ACEI/ARB 2,458 (88.3%) 790 (61.1%) \0.001
Beta-blocker 2,352 (84.5%) 669 (51.7%) \0.001
Diuretic 2,213 (79.5%) 680 (52.6%) \0.001
Aldosterone antagonist 1,290 (46.3%) 61 (4.7%) \0.001
Signs and symptoms
NYHA class 2.4 ± 0.6 2.0 ± 0.6 \0.001
SF-36 physical functioning score 49.6 ± 28.3 54.4 ± 27.7 \0.001
Dyspnea on exertion 2,424 (87.0%) 1,088 (84.1%) 0.013
Dyspnea at rest 327 (11.7%) 88 (6.8%) \0.001
Peripheral edema 713 (25.6%) 432 (33.4%) \0.001
Neck vein distention 187 (6.7%) 31 (2.4%) \0.001
Pulmonary rales 317 (11.4%) 52 (4.0%) \0.001
Number of symptoms 1.4 ± 1.0 1.3 ± 0.8 \0.001
Echocardiography
Left ventricular ejection fraction 31.2 ± 9.4 62.0 ± 8.4 n.a.*
End-diastolic LV diameter (mm) 62.3 ± 10.1 48.2 ± 7.6 \0.001
Comorbidities (n)
Diabetes mellitus 864 (31.0%) 313 (24.2%) \0.001
Hypertension 1,709 (61.4%) 1,014 (78.4%) \0.001
Hyperlipidemia 1,638 (58.8%) 699 (54.0%) 0.004
Hyperuricemia 1,086 (39.0%) 252 (19.5%) \0.001
Coronary artery disease 1,286 (46.2%) 405 (31.3%) \0.001
Renal dysfunction 962 (34.5%) 341 (26.4%) \0.001
Anemia 610 (21.9%) 183 (14.1%) \0.001
Obesity 746 (26.8%) 486 (37.6%) \0.001
COPD 421 (15.1%) 163 (12.6%) 0.035
Peripheral artery disease 292 (10.5%) 98 (7.6%) \0.001
Cerebrovascular disease 308 (11.1%) 117 (9.0%) \0.001
Atrial ﬁbrillation 581 (20.9%) 124 (9.6%) \0.001
Number of comorbidities 3.8 ± 2.1 3.2 ± 1.9 \0.001
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in SF-36 PF score was explained by sex and age only
compared with HFrEF (Fig. 3b). Again, adding echocar-
diographic variables did not improve the multivariate
model in HFpEF, while some improvement was noted for
HFrEF, and the inclusion of all comorbidities further
improved r
2 by 7.6%. In HFpEF, comorbidities added
12.1% and thereby approximately doubled the explained
variance, resulting in an r
2 of 25.1%. The variance
explained by comorbidities was therefore 1.59-fold higher
in HFpEF than in HFrEF. The overall explained variance of
SF-36 PF in HFpEF by sex, age, echocardiographic vari-
ables and comorbidities was 1.49-fold larger than in
HFrEF, even though the echocardiographic variables had
no impact on r
2 in HFpEF.
Discussion
To our knowledge, our analysis is the ﬁrst to evaluate the
relative impact of multiple comorbidities on physical
function in CHF in general, and in HFpEF and HFrEF in
particular.
We ﬁnd that patients with HFpEF are signiﬁcantly less
symptomatic than those with HFrEF. Of this lower CHF
symptom load in absolute terms, a relatively larger part is
explained by comorbidities, leaving a smaller fraction to be
explained by heart failure itself (or possibly other factors).
This is in spite of higher frequencies for most of the major
comorbidities investigated and a higher number of
comorbidities per patient in HFrEF.
CHF is a disease primarily of the elderly [1]; comor-
bidities are prevalent in these patients [4] and will be more
so in the future due to an aging population [15]. At the
same time, specialization and subspecialization continues
to be on the rise [16, 17], resulting in a strong focus of
different specialists on individual diseases from their
respective area of expertise, which may in turn compromise
the care for other comorbidities [18]. It has previously been
shown that comorbidities have an impact on hospitaliza-
tions and mortality in patients with CHF [4, 19]. Our data
complement this report, as we ﬁnd a signiﬁcant impact on
patients’ physical impairment in a large and diverse CHF
population from observational as well as interventional
trials with a harmonized basic data set. Comorbidities are
therefore associated with relevant suffering in daily life in
patients with CHF. At the same time, they strongly inﬂu-
ence the main symptom that leads to a CHF-oriented
diagnostic workup and is used to judge the course of dis-
ease and success of physicians’ interventions. This obser-
vation may appear to be obvious and intuitive. However, if
that is so, the above-mentioned trends in the organization
of medical care might consequentially be considered sub-
optimal and counterintuitive.
All individual comorbidities had a signiﬁcant impact on
physical impairment in at least one of both heart failure
groups. Several of these (such as COPD, history of stroke,
atrial ﬁbrillation, anemia or diabetes) generally limit
exercise capacity by themselves, even in patients without
CHF [20–23]. Others (like renal dysfunction or hyperuri-
cemia) may in fact rather be indicators of more advanced
and therefore more symptomatic CHF [24, 25]. Similarly,
the association of hypertension and hyperlipidemia with a
lower NYHA class in HFrEF may be due to the phenom-
enon of reverse epidemiology, i.e., the association of low
blood pressure and lower lipid levels with an adverse
prognosis and more advanced disease [26]. Such an effect
was not detectable for hypertension in HFpEF, and
hyperlipidemia actually worsened NYHA class and SF-36
PF score. This differential impact on physical function
contrasts with a recent report that showed a similar impact
of hyperlipidemia and hypertension on prognosis in HFrEF
as compared to HFpEF. Further studies will be needed to
better understand the associations of comorbidities with
Fig. 1 Distribution across
a NYHA grades and
b individual number of CHF
symptoms in patients with
HFrEF (open columns)o r
HFpEF (ﬁlled columns)
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Hypertension may have a stronger negative impact on
HFpEF due to ventriculo-vascular coupling [27] and
because it is a key factor for the development of left ven-
tricular hypertrophy [28] and diastolic dysfunction [29].
Alternatively, the reverse association of low blood
Table 2 Impact on NYHA
class and SF-36 physical
functioning scale of
comorbidities, corrected
for age and sex
Separate estimates are given for
HFrEF and HFpEF subgroups
when the p value for interaction
of comorbidity and ventricular
function is signiﬁcant (\0.05) or
borderline (\0.1)
Comorbidity Impact on NYHA class Impact on SF-36 PFS
Odds ratio (95% CI) p value Coefﬁcient (95% CI) p value
Comorbidities without signiﬁcant interaction
COPD
Interaction 0.18 0.10
Common estimate 1.82 (1.54; 2.15) \0.001 -12.79 (-10.27; -15.30) \0.001
Cerebrovascular disease
Interaction 1.00 0.43
Common estimate 1.49 (1.26; 1.77) \0.001 -8.27 (-5.35; -11.18) \0.001
Atrial ﬁbrillation
Interaction 0.10 0.73
Common estimate 1.59 (1.37; 1.83) \0.001 -6.14 (-3.74; -8.55) \0.001
Diabetes
Interaction 0.79 0.09
Common estimate 1.26 (1.11; 1.45) \0.001 -5.82 (-3.82; -7.83) \0.001
Renal dysfunction
Interaction 0.60 0.16
Common estimate 1.51 (1.31; 1.73) \0.001 -7.41 (-5.38; -9.44) \0.001
Anemia
Interaction 0.36 0.25
Common estimate 1.77 (1.51; 2.07) \0.001 -9.74 (-7.46; -12.02) \0.001
Hyperuricemia
Interaction 0.58 0.10
Common estimate 1.60 (1.40; 1.82) \0.001 -6.53 (-4.61; 8.45) \0.001
Comorbidities with signiﬁcant interaction
Obesity
Interaction 0.01 0.68
HFrEF subgroup 1.10 (0.93; 1.30) 0.26
HFpEF subgroup 1.53 (1.22; 1.92) \0.001
Common estimate -4.35 (-2.39; -6.30) \0.001
Hypertension
Interaction 0.06 0.02
HFrEF subgroup 0.75 (0.64; 0.88) 0.001 0.28 (-2.09; 2.66) 0.82
HFpEF subgroup 0.89 (0.66; 1.18) 0.41 -4.6 (-0.65; -8.61) 0.02
Hyperlipidemia
Interaction \0.001 \0.001
HFrEF subgroup 0.75 (0.65; 0.87) \0.001 1.82 (-0.41; 4.04) 0.11
HFpEF subgroup 1.38 (1.11; 1.73) 0.005 -6.28 (3.16; 9.40) \0.001
Coronary artery disease
Interaction 0.001 0.001
HFrEF subgroup 0.94 (0.80; 1.10) 0.40 -5.62 (-3.24; -7.99) \0.001
HFpEF subgroup 1.71 (1.33; 2.19) \0.001 -12.01 (-8.59; -15.42) \0.001
Peripheral artery disease
Interaction 0.02 0.04
HFrEF subgroup 1.23 (0.97; 1.56) 0.083 -10.70 (-7.14; -14.26) \0.001
HFpEF subgroup 1.94 (1.28; 2.93) 0.002 -17.73 (-11.94; -23.52) \0.001
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HFpEF, an explanation that would also be in concordance
with the overall lower symptom load, indicating a less
advanced disease stage in our HFpEF group. This alter-
native explanation could also account for the differential
impact of obesity. While this comorbidity would be
expected to lead to worse physical functioning, as observed
in our HFpEF group, this effect has likely been offset by
reverse epidemiology in the HFrEF group, leading to a
neutral impact on the NYHA class. The more pronounced
inﬂuence of PAOD may be indicative of the relevance of
ventriculo-vascular coupling for the development of
HFpEF [27, 30].
Why should the overall effect of comorbidities on
physical function be greater in HFpEF than in HFrEF
patients, as observed in our analysis?
Patients with HFpEF are a heterogeneous group. While
the presence of a lowered LV-EF adds some cardio-spec-
iﬁcity to the clinical diagnosis of CHF, its absence does
not. HFpEF therefore by principle will be much less spe-
ciﬁc for cardiac abnormalities as the underlying pathology
for the clinical picture of heart failure. Consequentially,
basing HFpEF exclusively on the clinical picture and the
absence of major abnormalities in systolic function will
lead to a higher number of cases falsely attributed to car-
diac abnormalities [31]. It is likely that some of these cases
will have non-cardiac comorbidities as a main reason for
reduced physical function.
It is also possible that comorbidities have a relatively
higher impact on physical impairment in patients with true
CHF due to cardiac (mainly diastolic) dysfunction with
normal ejection fraction. This would suggest that diastolic
Fig. 2 Odds ratios in multivariate analyses for a higher NYHA class and b SF-36 physical functioning score in HFrEF or HFpEF
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physical function than relevant systolic dysfunction (which
is usually accompanied by some degree of diastolic func-
tion and in that sense is additive). Although the similarities
in morbidity and mortality [6, 7] as well as health-care
utilization [32] between HFpEF and HFrEF may seem to
argue against this, adverse prognosis in HFpEF has been
reported to be associated in a large part with non-CHF
events [8–10] and a differential inﬂuence of gender has
been described [33]. Further supporting this hypothesis is
the fact that the echocardiographic variable most strongly
associated with physical function in each group had a much
stronger effect in HFrEF than in HFpEF. Cardiac abnor-
malities in HFpEF may therefore bear a smaller part of
adverse prognosis and, as we show here, of impairment in
physical function.
Our results strongly support two major calls to
researchers and physicians dealing with heart failure
patients: Firstly, a diagnosis of HFpEF must not be based
on the absence of systolic abnormalities, but rather on the
Fig. 3 a AUC to predict higher
NYHA class and b r
2 of
multivariate linear model for
SF-36 physical functioning
score according to the set of
covariates used for model
building
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123presence of non-systolic cardiac abnormalities. Otherwise,
HFpEF populations will by conception include a larger
number of non-cardiac etiologies for impaired physical
function, making clinical research aimed at speciﬁc treat-
ments for HFpEF challenging (and some would argue,
impossible) [31, 34].
Secondly, caring for patients with CHF must include a
strong focus on the diagnosis and treatment of comorbid-
ities, because patients’ suffering can only be partly
addressed by treating their cardiac abnormalities only.
Some limitations of our analysis have to be addressed.
Although we were limited in our analysis to a certain set
of comorbidities, several other diseases that were not
assessed in all of the studies included may also have an
impact on physical function in heart failure patients (e.g.,
sleep-disordered breathing, depression, cognitive dys-
function, thyroid disorders, osteoporosis). We only had a
basic set of echocardiographic data to include in our
analysis. Including more recent markers of diastolic
function might well have shown a stronger effect on
physical function. However, smaller left ventricular
end-diastolic dimensions have been shown to be char-
acteristic of patients with HFpEF [27, 35] and were
signiﬁcantly associated with lower NYHA class in our
cohort. Some of the evidence we present is of an indirect
nature. A direct estimate of the impact of HFrEF or
HFpEF itself on physical function in comparison with a
non-CHF population would be most interesting, but
cannot be derived from our data set. The diagnosis of
comorbidities was largely history based and therefore
suboptimal. However, we assume that such an approach
will lead to under- rather than overdiagnosis and more
cases of e.g., COPD, CAD or (paroxysmal) atrial ﬁbril-
lation would have been revealed by more intensive
diagnostic testing, increasing the relative impact of
comorbidities on physical function. Similarly, a conﬁr-
mation of our ﬁndings in an unselected patient popula-
tion will be necessary. Because such a population will be
older and more comorbid, a different impact of comor-
bidities cannot be excluded.
Conclusion
Comorbidities have a signiﬁcant impact on NYHA class
and SF-36 PF in HFrEF as well as in HFpEF. The inﬂuence
of individual comorbidities is different in HFrEF as com-
pared to HFpEF. The overall impact of comorbidities is
higher in HFpEF than in HFrEF. This implies that
comorbidities should play a larger role in the differential
diagnosis of patients with exertional dyspnea and preserved
ejection fraction. Focusing treatment on comorbidities may
be more beneﬁcial in HFpEF than in HFrEF.
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